PT - JOURNAL ARTICLE AU - Parham Habibzadeh AU - Abdollah Sarami AU - Mahboobeh Yadollahie AU - Kourosh Hashemiasl AU - Arezoo Salahi AU - Farrokh Habibzadeh TI - QT Interval Prolongation in Patients Treated for COVID-19 AID - 10.1101/2020.12.10.20246975 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.10.20246975 4099 - http://medrxiv.org/content/early/2020/12/11/2020.12.10.20246975.short 4100 - http://medrxiv.org/content/early/2020/12/11/2020.12.10.20246975.full AB - Background Many of the drugs commonly used for the treatment of COVID-19 cause QT interval prolongation and increase the risk of life-threatening cardiac arrhythmias. It has been shown that maintaining serum potassium and magnesium levels above 4 and 3 mg/dL, respectively, would prevent the QTc prolongation.Objective To determine if keeping only the serum magnesium level above 3 mg/dL could be considered an effective measure to prevent QTc prolongation in patients with COVID-19 receiving these drugs.Methods In a retrograde observational study, QTc interval was measured in 14 patients diagnosed with COVID-19 before and 3 days after initiation of treatment with either hydroxychloroquine or lopinavir-ritonavir, while their serum magnesium levels were kept ≥3 mg/dL.Results The baseline QTc interval of 412 (SD 36) ms significantly increased by an average of 34 (95% CI 13 to 55) ms after 3 days of treatment. 5 patients, mostly those with lower serum potassium levels, had QTc prolongation ≥60 ms.Conclusion Although it seems that the risk of fatal cardiac arrhythmias in this setting is not high, it is prudent to monitor the serum electrolytes, particularly potassium, in patients with COVID-19 who are treated with either hydroxychloroquine or lopinavir-ritonavir.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Petroleum Industry Health Organization Institutional Review Board. Informed written consents were taken from all study participants. This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data are available from the corresponding author, if reasonable reasons are provided.